Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Early treatment with neuraminidase inhibitors is associated with reduced mortality in severe influenza. There is a need for pragmatic and efficient trial designs, to test a variety of investigational therapeutics, individually and in combination.